Results 291 to 300 of about 2,360,658 (324)

Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer

Nature, 2022
Kohei Shitara, Jaffer A Ajani, Lucjan S Wyrwicz   +2 more
exaly  

Retreatability of BC Sealer and AH Plus root canal sealers using new supplementary instrumentation protocol during non-surgical endodontic retreatment

Clinical Oral Investigations, 2020
B. Crozeta, F. Lopes, Renato Menezes Silva, Y. Silva-Sousa, Letícia Freiria Moretti, M. Sousa-Neto   +5 more
semanticscholar   +1 more source

Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial

Nature Medicine, 2023
Manish A Shah, Kohei Shitara, Jaffer A Ajani   +2 more
exaly  

The long-term sealing ability of AH 26 and AH plus used with three gutta-percha obturation techniques.

Quintessence international (Berlin, Germany : 1985), 2004
To evaluate and compare the sealability of root fillings in extracted teeth by using AH 26 and AH Plus in conjunction with three different obturation techniques.Root canals of 940 single-rooted teeth were prepared according to the crown-down/stepback technique (using both 2.5% NaOCl and File-Eze) before lateral condensation and hybrid condensation of ...
Roeland J G, De Moor, Mieke A A, De Bruyne   +1 more
openaire   +1 more source

Immunotherapies for hepatocellular carcinoma

Nature Reviews Clinical Oncology, 2021
, Florian Castet, Mala K Maini
exaly  

Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial

Nature Medicine, 2022
, Ewa Kalinka-Warzocha, Ruben G W Quek
exaly  

Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial

Nature Medicine, 2021
Ken Kato, Yoshito Komatsu, Satoshi Yuki
exaly  

Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial

Nature Medicine, 2020
Nick van Dijk, Alberto Gil-Jimenez, Karina Silina   +2 more
exaly  

Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial

Nature Medicine, 2023
Vivek Subbiah, Ulrik Lassen, J-Y Blay
exaly  

Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma

Nature Medicine, 2020
Jianjun Gao, Omar Alhalabi, Arlene O Siefker-Radtke   +2 more
exaly